Citadel Advisors’s CONMED CNMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,400
| Closed | -$229K | – | 12906 |
|
|
2025
Q2 | $229K | Sell |
4,400
-1,100
| -20% | -$60.4K | ﹤0.01% | 10401 |
|
|
2025
Q1 | $332K | Buy |
5,500
+400
| +8% | +$25.8K | ﹤0.01% | 9359 |
|
|
2024
Q4 | $349K | Buy |
5,100
+200
| +4% | +$13.9K | ﹤0.01% | 9343 |
|
|
2024
Q3 | $352K | Buy |
4,900
+2,000
| +69% | +$141K | ﹤0.01% | 8978 |
|
|
2024
Q2 | $201K | Buy |
2,900
+1,600
| +123% | +$117K | ﹤0.01% | 9930 |
|
|
2024
Q1 | $104K | Buy |
1,300
+900
| +225% | +$80.2K | ﹤0.01% | 11306 |
|
|
2023
Q4 | $43.8K | Sell |
400
-36,400
| -99% | -$3.76M | ﹤0.01% | 11919 |
|
|
2023
Q3 | $3.71M | Buy |
36,800
+24,400
| +197% | +$2.8M | ﹤0.01% | 4128 |
|
|
2023
Q2 | $1.69M | Sell |
12,400
-300
| -2% | -$36.6K | ﹤0.01% | 5470 |
|
|
2023
Q1 | $1.32M | Sell |
12,700
-18,600
| -59% | -$1.8M | ﹤0.01% | 6192 |
|
|
2022
Q4 | $2.77M | Buy |
31,300
+19,400
| +163% | +$1.61M | ﹤0.01% | 4880 |
|
|
2022
Q3 | $954K | Buy |
+11,900
| New | +$1.12M | ﹤0.01% | 7091 |
|
|
2022
Q2 | – | Sell |
-17,500
| Closed | -$2.6M | – | 12993 |
|
|
2022
Q1 | $2.6M | Sell |
17,500
-5,500
| -24% | -$768K | ﹤0.01% | 5497 |
|
|
2021
Q4 | $3.26M | Buy |
23,000
+10,000
| +77% | +$1.42M | ﹤0.01% | 5170 |
|
|
2021
Q3 | $1.7M | Sell |
13,000
-33,700
| -72% | -$4.41M | ﹤0.01% | 6774 |
|
|
2021
Q2 | $6.42M | Buy |
46,700
+11,900
| +34% | +$1.63M | ﹤0.01% | 3916 |
|
|
2021
Q1 | $4.54M | Buy |
34,800
+2,600
| +8% | +$313K | ﹤0.01% | 4457 |
|
|
2020
Q4 | $3.61M | Buy |
+32,200
| New | +$3.05M | ﹤0.01% | 4262 |
|
|
2020
Q1 | – | Sell |
-2,000
| Closed | -$224K | – | 9641 |
|
|
2019
Q4 | $224K | Sell |
2,000
-3,300
| -62% | -$352K | ﹤0.01% | 8015 |
|
|
2019
Q3 | $510K | Sell |
5,300
-300
| -5% | -$28.2K | ﹤0.01% | 6709 |
|
|
2019
Q2 | $479K | Buy |
+5,600
| New | +$460K | ﹤0.01% | 6882 |
|
|
2016
Q1 | – | Sell |
-1,100
| Closed | -$48K | – | 6907 |
|
|
2015
Q4 | $48K | Sell |
1,100
-1,500
| -58% | -$65.1K | ﹤0.01% | 7341 |
|
|
2015
Q3 | $124K | Buy |
2,600
+1,500
| +136% | +$82.3K | ﹤0.01% | 6732 |
|
|
2015
Q2 | $64K | Sell |
1,100
-4,800
| -81% | -$259K | ﹤0.01% | 7483 |
|
|
2015
Q1 | $298K | Buy |
5,900
+3,000
| +103% | +$147K | ﹤0.01% | 5657 |
|
|
2014
Q4 | $130K | Buy |
2,900
+600
| +26% | +$25.1K | ﹤0.01% | 6411 |
|
|
2014
Q3 | $85K | Buy |
2,300
+2,000
| +667% | +$79.3K | ﹤0.01% | 6550 |
|
|
2014
Q2 | $13K | Buy |
+300
| New | +$13.6K | ﹤0.01% | 7484 |
|
Other funds holding CNMD
VPM
VCM
CB
Citadel Advisors's CNMD Position: Q1 2026 in Review
Citadel Advisors reduced its CONMED (CNMD) stake by 61% in Q1 2026, selling an estimated $16M and leaving 246,930 shares worth $8.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3444.
Citadel Advisors first reported a position in CNMD in Q3 2013 and has held it in 49 quarters since. The position peaked at $33.8M in Q4 2022. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.
- Citadel Advisors held 246,930 shares of CONMED worth $8.73M as of Q1 2026.
- Citadel Advisors sold 393,643 CONMED shares in Q1 2026, an estimated $16M.
- CONMED made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3444 holding.
- Citadel Advisors first reported a position in CONMED in Q3 2013 and has held it in 49 quarters since.
- Citadel Advisors's CONMED position peaked at $33.8M in Q4 2022.
- 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.